Use Of Epiontis ID To Support Understanding Therapeutic Efficacy In A Phase 2 Psoriasis Trial

Psoriasis is driven by complex immune signaling, and even when symptoms subside, inflammatory cells can linger in the skin, setting the stage for future flare-ups. Eli Lilly’s Phase II trial investigates mirikizumab, a monoclonal antibody that targets the p19 subunit of IL-23, a cytokine that fuels IL-17 production from T cells and other immune cells. 205 patients were enrolled who have moderate to severe plaque psoriasis. Epiontis ID (Epigenetic cell counting) measured the levels of CD3, Treg, and IL-17-producing cells in skin biopsies to assess how mirikizumab modulates immune activity at the cellular level.

The findings could help clarify how IL-23 inhibition influences long-term disease control and immune cell persistence in the skin. For those exploring targeted immunotherapies and their impact on chronic inflammatory conditions, this study offers a closer look at the mechanisms behind sustained therapeutic response.